NKARTA INC (NKTX)       14.35  +1.2 (+9.13%)

14.35  +1.2 (+9.13%)

US65487U1088 - Common Stock - After market: 14.35 0 (0%)

NKARTA INC14.35

NASDAQ:NKTX (10/4/2022, 7:00:02 PM)+1.2 (+9.13%)

After market: 14.35 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-11 2022-08-11/amc Earnings (Next) 11-08 2022-11-08
Ins Owners 0.82% Inst Owners 90.31%
Market Cap 698.23M Shares 48.66M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 85.56
IPO 07-10 2020-07-10

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NKTX Daily chart

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 127 full-time employees. The company went IPO on 2020-07-10. The company has two co-lead products, NKX101 and NKX019, in ongoing Phase I clinical trials. Its platform incorporates technologies that enable to generate supply of NK cells and enhance cell fitness and tumor microenvironment evasion, freeze, store and thaw its engineered NK cells for off-the-shelf use for the treatment of cancer. Its product candidates and discovery programs NKX101 is designed to innate NK biology to detect and kill cancerous cells. Its primary activating receptor NKG2D, works through the detection of stress ligands displayed by cancerous cells. The company has engineered NKX101 to increase the cancer cell killing ability of its engineered NK cells by raising levels of NKG2D. Its NKX019 treats a variety of B-cell malignancies by targeting the CD19 antigen that is found on these types of cancerous cells.

Company Info

NKARTA INC

6000 Shoreline Court, Suite 102

South San Francisco CALIFORNIA 94080

P: 14155824923.0

CEO: Paul J. Hastings

Employees: 127

Website: https://www.nkartatx.com/

NKTX News

News Image12 days ago - InvestorPlace7 Unknown Biotech Stocks That Could Rocket in 2023

Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.

News Image16 days ago - Market News VideoNKTX Crosses Below Key Moving Average LevelNews Image2 months ago - Nkarta, Inc.Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights

Positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients with relapsed /...

News Image2 months ago - Market News VideoBullish Two Hundred Day Moving Average Cross - NKTXNews Image2 months ago - Nkarta, Inc.Nkarta Announces Key Senior Leadership Team Appointments

Ralph Brandenberger, PhD, promoted to Chief Technical OfficerYvonne Li, MBA, promoted to Chief Administrative OfficerEvolution of Nkarta leadership team to...

News Image3 months ago - Market News VideoNKTX Crosses Above Key Moving Average Level

NKTX Twits

Here you can normally see the latest stock twits on NKTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example